Financial Performance - Total revenue for the first half of 2019 was CNY 385,720,035.51, a decrease of 0.56% compared to CNY 387,877,244.39 in the same period last year[21]. - Net profit attributable to shareholders was CNY 16,271,846.16, down 66.26% from CNY 48,221,200.83 year-on-year[21]. - Net profit after deducting non-recurring gains and losses was CNY 26,352,666.08, a decrease of 48.09% compared to CNY 50,764,191.15 in the previous year[21]. - Basic and diluted earnings per share were both CNY 0.06, a decline of 66.67% from CNY 0.18 in the previous year[21]. - Operating profit was CNY 44,728,842.29, down 48.76% year-on-year, while net profit decreased by 54.66% to CNY 30,249,197.64[48]. - The estimated cumulative net profit for the period from the beginning of the year to the next reporting period is expected to be CNY 20.50 million, a decrease of 65.00% compared to the same period last year, which was CNY 58.57 million[100]. - Basic earnings per share are projected to be CNY 0.078, down 64.54% from CNY 0.22 in the same period last year[100]. - The expected net profit for the period from July 1 to September 30 is estimated to be CNY 7.52 million, representing a 50.00% decrease compared to CNY 10.35 million in the same period last year[100]. Cash Flow and Assets - Net cash flow from operating activities increased significantly to CNY 136,078,889.64, up 275.38% from CNY 36,251,267.16 in the same period last year[21]. - Total assets at the end of the reporting period were CNY 1,863,169,454.87, a decrease of 12.70% from CNY 2,134,224,255.98 at the end of the previous year[21]. - Current assets increased from CNY 876,130,939.30 to CNY 1,081,805,376.43, representing a growth of about 23.3%[191]. - Non-current assets decreased significantly from CNY 1,258,093,316.68 to CNY 781,364,078.44, a drop of approximately 37.9%[191]. - Cash and cash equivalents increased to CNY 74,637,631.36 from CNY 15,086,122.33, a significant increase of about 394.5%[192]. - The company’s cash and cash equivalents as of June 30, 2019, were approximately ¥292.45 million, an increase from ¥202.23 million at the end of 2018[182]. Investments and R&D - R&D investment increased by 23.36% to CNY 49,590,712.20, accounting for 12.86% of total revenue, focusing on ECHOSENS liver disease diagnostic technology[58]. - The company is focusing on product R&D to strengthen its competitive edge and meet diverse market needs, particularly in the liver disease sector[35]. - The focus of research and development is on liver fibrosis diagnosis, with plans to integrate various diagnostic methods and develop a comprehensive liver disease assessment system[106]. - The company plans to expand its business scope through continuous mergers and acquisitions in medical devices, therapeutic drugs, and medical services to enhance profitability and risk resistance[101]. Market Position and Strategy - The company experienced a decline in drug sales and gross margin due to rising raw material costs and adjustments in sales models, prompting efforts to diversify sales channels and control costs[31]. - The company is actively pursuing strategic collaborations in internet healthcare and chronic disease management, aiming to enhance service delivery and patient outcomes[37]. - The company plans to leverage its academic and technical advantages to lower barriers for medical institutions and patients, further solidifying its leadership in non-invasive liver diagnostics[35]. - The company is focusing on expanding its market presence and enhancing product development strategies[200]. - Future outlook includes potential mergers and acquisitions to strengthen market position[200]. Risk Management - There are no significant adverse risk factors affecting the company's operational, financial status, or ongoing profitability[6]. - The company emphasizes the importance of risk awareness regarding forward-looking statements in the report[5]. - The company faces risks from increased competition in the liver disease diagnosis and treatment market, which may pressure product sales and new product development[102]. - The company is taking measures to mitigate the impact of raw material price fluctuations, including direct procurement and price locking strategies[105]. Corporate Governance and Compliance - The company has commitments in place to avoid competition with its controlling shareholders, ensuring no direct or indirect business competition[116]. - The company has a share lock-up commitment for 36 months post-IPO, restricting the transfer of shares held by major shareholders[116]. - The company has not faced any penalties or corrective actions during the reporting period, indicating compliance with regulations[125]. - The company has not reported any major asset or equity sales during the reporting period[96]. - The company has not engaged in any derivative investments or entrusted loans during the reporting period[94][95]. Project Updates - The company has decided to terminate the health technology park project due to the recovery of state-owned land rights[74]. - The company has not achieved the planned progress and expected returns for several projects due to various reasons[78]. - The Furu Medical Center project is 45.08% complete, with no realized income due to urban planning adjustments[71]. - The liver fibrosis online diagnostic system (FSTM) project has a cumulative investment of CNY 21.61 million, representing 33.25% of the planned investment[80]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 18,748[159]. - The largest shareholder, Wang Guanyi, holds 11.31% of the shares, totaling 29,754,138 shares[159]. - China National Investment Corporation holds 9.18% of the shares, totaling 24,160,000 shares[159].

Financial Performance - The company reported a total revenue of 256,334,867 RMB for the year 2018, with no cash dividends or stock bonuses distributed to shareholders [5]. - The company's operating revenue for 2018 was ¥867,029,327, representing a year-on-year increase of 5.31% compared to ¥849,675,042 in 2017 [14]. - The net profit attributable to shareholders decreased by 42.05% to ¥35,416,101 from ¥71,866,910 in 2017 [14]. - The net profit after deducting non-recurring gains and losses was ¥39,538,967, down 36.83% from ¥73,346,797 in the previous year [14]. - Cash flow from operating activities was ¥78,347,686, a decline of 40.52% compared to ¥126,160,834 in 2017 [14]. - Basic and diluted earnings per share fell by 43.48% to ¥0.13 from ¥0.27 in 2017 [14]. - Total assets at the end of 2018 were ¥2,134,224,255, a decrease of 14.99% from ¥2,502,614,050 in 2017 [15]. - The company's weighted average return on equity was 2.36%, down from 4.82% in 2017 [14]. - Operating profit was 123.30 million yuan, a decrease of 11.40% year-on-year; total profit was 116.15 million yuan, down 13.07% from the previous year [39]. Market Strategy and Product Development - The company plans to expand its market presence and enhance its product offerings, focusing on innovative diagnostic technologies like FibroScan and FibroMeter [9]. - The company’s future outlook includes a commitment to research and development in non-invasive diagnostic systems for liver fibrosis [9]. - The company aims to establish a long-term product business model and integrate liver disease diagnosis and treatment methods to promote revenue growth [29]. - The company aims to enhance its core competitiveness in diagnostic technology and product development to meet diverse market needs [95]. - The company is actively pursuing new strategies for market expansion and technological innovation to enhance its competitive edge [179]. - The company is focusing on local production in China, including the launch of domestically produced FibroScan PRO products [29]. Research and Development - Research and development (R&D) expenses for 2018 amounted to 104,705,096.95 yuan, representing 12.08% of the company's operating revenue, with a year-on-year increase of 7.33% [62]. - The number of R&D personnel decreased to 97 in 2018, making up 15.49% of the total workforce, down from 20.45% in 2017 [62]. - The company is focusing its R&D efforts on liver fibrosis diagnostics, integrating various testing methods and medical information technology tools [101]. - The company has achieved satisfactory results in its research and development efforts, including data modeling and patent applications [85]. Shareholder and Governance - The board of directors has approved a profit distribution plan based on the total shares outstanding, indicating a focus on capital preservation [5]. - The company has implemented a cash dividend policy, distributing RMB 1 per 10 shares to shareholders based on its total share capital of 263,053,100 shares as of December 31, 2017 [105]. - The company’s independent directors fulfilled their responsibilities and ensured the protection of minority shareholders' rights [106]. - The company has committed to avoiding any activities that would constitute competition with its existing and future business [112]. - The company has established a commitment to avoid any potential conflicts of interest with its controlling shareholder, ensuring the protection of shareholder interests [115]. Operational Efficiency - The company has established a real-time data transmission system for its online diagnostic services, enhancing operational efficiency [9]. - The integration of machine learning and natural language processing has improved service efficiency, reducing the time doctors spend per patient by 40% without compromising service quality [30]. - The "Love Liver Lifetime Health Management Center" provided chronic disease management services to 40,000 patients, improving service efficiency by reducing doctor-patient interaction time by 40% [42]. Legal and Compliance - The company has not issued any non-standard audit reports during the reporting period, reflecting compliance with accounting standards [118]. - The company is currently involved in a patent infringement lawsuit in Germany, with potential penalties of up to €250,000 for violations [124]. - The company reported a total economic loss compensation of RMB 30 million due to patent infringement [127]. Employee and Management Structure - The total number of employees in the company is 626, with 182 in the parent company and 444 in major subsidiaries [194]. - The professional composition includes 80 production personnel, 189 sales personnel, and 97 technical personnel [195]. - The company has a performance bonus system where bonuses typically range from 15% to 20% of monthly salary based on performance evaluations [196]. - The management team includes experienced professionals with backgrounds in finance, medicine, and technology, enhancing the company's strategic capabilities [182]. Financial Investments and Acquisitions - The company has a remaining balance of 2,192.89 million yuan in its fundraising account as of December 31, 2018 [82]. - The acquisition of the French company Echosens was completed for 18,501 million yuan, representing a 100% stake [83]. - The company has increased its stake in Echosens S.A.S. from 46.20% to 50.27%, with an additional investment cost of 11,122.00 euros [92]. Social Responsibility and Community Engagement - The company received the "2018 Best Public Welfare Practice Award" for its contributions to hepatitis prevention and control in China [146]. - The company upgraded its "Love Liver for Life" project to provide chronic liver disease family doctor services, enhancing health management and consultation services [145].

Financial Performance - Total revenue for Q1 2019 was CNY 174,220,949.20, a decrease of 0.43% compared to CNY 174,973,279.78 in the same period last year[8]. - Net profit attributable to shareholders was CNY 6,665,206.20, down 34.12% from CNY 10,116,444.70 year-on-year[8]. - Net profit excluding non-recurring gains and losses was CNY 6,595,707.16, a decrease of 34.36% compared to CNY 10,048,083.41 in the previous year[8]. - Basic earnings per share decreased by 25.00% to CNY 0.03 from CNY 0.04 in the previous year[8]. - The gross profit margin for Q1 2019 was approximately 11.9%, down from 13.6% in the same quarter last year[69]. - The total comprehensive income for Q1 2019 was CNY -12,971,227.24, compared to CNY 8,575,514.84 in Q1 2018, indicating a significant decline[76]. - The net profit for the current period is 1,019,002.81, a decrease from 7,224,727.15 in the previous period, representing a decline of approximately 86.9%[80]. - The total profit for the current period is 1,217,512.96, down from 8,652,769.87, indicating a decrease of about 85.9%[80]. Cash Flow and Liquidity - Net cash flow from operating activities increased significantly to CNY 47,456,240.84, up 1,183.36% from CNY 3,697,824.28 in the same period last year[8]. - Cash inflow from operating activities totaled 209,129,688.17, compared to 163,262,491.82 in the previous period, reflecting an increase of approximately 28.1%[86]. - Cash outflow from operating activities was 161,673,447.33, slightly up from 159,564,667.54, showing a marginal increase of about 1.3%[86]. - The cash and cash equivalents at the end of the period totaled 199,986,472.73, down from 470,045,444.55 in the previous period, indicating a decrease of approximately 57.6%[88]. - Cash flow from financing activities resulted in a net outflow of -900,209.65, compared to -192,466,523.97 in the previous period, showing an improvement[88]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,091,250,956.75, a decrease of 2.01% from CNY 2,134,224,255.98 at the end of the previous year[8]. - Total current assets decreased from ¥876,130,939.30 to ¥848,175,859.49, a decline of approximately 3.0%[52]. - Total liabilities decreased from ¥621,947,047.93 to ¥592,339,907.37, a decline of about 4.8%[55]. - Total equity decreased from ¥1,512,277,208.05 to ¥1,498,911,049.38, a decrease of approximately 0.9%[58]. - The company reported a total asset value of $2,134,224,255.98, with total liabilities amounting to $621,947,047.93, indicating a healthy asset-to-liability ratio[98]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 18,879[11]. - The largest shareholder, Wang Guanyi, held 11.31% of the shares, amounting to 29,754,138 shares[11]. Business Strategy and Development - The company plans to expand its business scope through acquisitions in medical devices, therapeutic drugs, and medical services[24]. - The company is focusing on developing liver fibrosis diagnostic products and integrating various liver disease testing methods[28]. - The company has initiated a plan to acquire 87.32% of Chengdu List Pharmaceutical Co., Ltd., which was disclosed on January 10, 2019[29]. - The company has decided to terminate the acquisition of List Pharmaceutical as per the board's resolution[33]. - The company plans to focus on the development and promotion of advanced diagnostic technologies through the acquisition of Echosens[40]. Research and Development - Research and development expenses increased to CNY 13,001,597.76, representing a rise of 22.4% compared to CNY 10,615,183.27 in the previous year[69]. Risks and Challenges - The company is facing risks from rising raw material prices, particularly for natural ingredients like Cordyceps, which has affected the gross margin of its main product[26]. - The company aims to mitigate raw material price fluctuations by directly purchasing from production areas and locking in prices in advance[26]. Compliance and Reporting - The first quarter report was not audited, indicating a need for caution in interpreting the financial data[105]. - The company has implemented new financial and leasing standards, which may affect future financial reporting[105].

Financial Performance - Net profit attributable to shareholders increased by 9.60% to CNY 10,349,809.37 for the current period[8] - The company reported a net profit attributable to shareholders of CNY 58,571,010.20 year-to-date, reflecting a 19.37% increase[8] - The net profit after deducting non-recurring gains and losses was CNY 10,912,072.82, up 19.76% for the current period[8] - Net profit for Q3 2018 was ¥10,537,565.43, a decrease of 31.1% from ¥15,314,773.09 in Q3 2017[40] - Net profit for the current period was ¥77.25 million, up from ¥67.08 million, reflecting an increase of 15.25%[47] Revenue and Costs - Operating revenue rose by 14.56% to CNY 196,260,606.39 for the current period[8] - Total operating revenue for Q3 2018 reached ¥196,260,606.39, an increase of 14.6% compared to ¥171,311,779.22 in the same period last year[38] - Operating costs for the same period were ¥178,954,408.77, up 19.0% from ¥150,364,749.10 year-over-year[38] - Total operating revenue for the current period reached ¥584.14 million, a slight increase from ¥583.18 million in the previous period, representing a growth of 0.16%[46] - Total operating costs decreased to ¥483.26 million from ¥497.28 million, marking a reduction of 2.04%[46] Assets and Liabilities - Total assets decreased by 12.89% to CNY 2,179,969,441.11 compared to the end of the previous year[8] - The company's current assets decreased to CNY 822,335,102.83 from CNY 1,233,449,663.04, reflecting a significant reduction of approximately 33.4%[32][34] - The company's total liabilities decreased to CNY 541,907,387.44 from CNY 570,982,246.81, a reduction of about 5.1%[34] - The total equity attributable to shareholders decreased to CNY 1,437,809,599.87 from CNY 1,502,520,319.04, reflecting a decline of approximately 4.3%[34] Cash Flow - Net cash flow from operating activities decreased by 84.01% to CNY 9,095,061.61 year-to-date[8] - The net cash flow from operating activities for Q3 2018 was ¥9,095,061.61, a decrease of 84.7% compared to ¥56,888,765.83 in the same period last year[54] - Total cash inflow from operating activities was ¥362,755,253.89, down 52.1% from ¥756,817,040.65 year-on-year[56] - The company reported a net decrease in cash and cash equivalents of ¥421,991,748.10 for the quarter, contrasting with an increase of ¥27,479,493.07 in the previous year[55] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 20,168[12] - The largest shareholder, Wang Guanyi, holds 11.31% of the shares, totaling 29,754,138 shares[12] - The company distributed a cash dividend of RMB 1 per 10 shares to all shareholders based on a total share capital of 263,053,100 shares as of December 31, 2017[25] Investments and Acquisitions - The company plans to acquire 62,985,383 shares of Chengdu List Pharmaceutical Co., Ltd., representing 87.322% of the target company's total shares[20] - Long-term equity investments rose by 30% attributed to changes in the scope of consolidation[19] - The company received a cash dividend from the French subsidiary, resulting in a 496% increase in cash paid for dividends, profits, or interest[19] Research and Development - Research and development expenses increased to ¥14,292,440.15, representing a 50.5% rise from ¥9,484,351.22 in the previous year[38] - Research and development expenses increased to ¥35.15 million from ¥31.41 million, showing a rise of 11.67%[46] Other Financial Metrics - The weighted average return on net assets was 0.73%, an increase of 0.09% compared to the previous period[8] - Basic and diluted earnings per share remained stable at ¥0.04 for both Q3 2018 and Q3 2017[41] - The comprehensive income total for Q3 2018 was ¥42,638,423.41, compared to a loss of ¥3,008,599.37 in the same quarter last year[41]

Financial Performance - Total revenue for the first half of 2018 was CNY 387,877,244.39, a decrease of 5.82% compared to CNY 411,868,230.13 in the same period last year[18]. - Net profit attributable to shareholders increased by 21.71% to CNY 48,221,200.83, up from CNY 39,621,101.35 year-on-year[18]. - Net profit after deducting non-recurring gains and losses rose by 23.82% to CNY 50,764,191.15, compared to CNY 40,999,689.14 in the previous year[18]. - Net cash flow from operating activities increased by 21.76% to CNY 36,251,267.16, compared to CNY 29,772,348.21 in the same period last year[18]. - Basic earnings per share rose by 12.50% to CNY 0.18, up from CNY 0.16 in the previous year[18]. - The company achieved an operating profit of 87,290,842.49 yuan, a year-on-year increase of 27.83%[46]. - The company reported a net profit for the first half of 2018 of CNY 66,717,215.19, an increase of 28.9% compared to CNY 51,767,413.69 in the previous year[154]. Assets and Liabilities - Total assets decreased by 13.27% to CNY 2,170,641,854.70 from CNY 2,502,614,057.97 at the end of the previous year[18]. - Net assets attributable to shareholders decreased by 6.46% to CNY 1,405,421,286.21 from CNY 1,502,520,319.04 at the end of the previous year[18]. - Cash and cash equivalents decreased by 13.63% to CNY 240.84 million, accounting for 11.10% of total assets compared to 24.73% in the previous year[59]. - Accounts receivable increased by 2.81% to CNY 283.40 million, representing 13.06% of total assets[59]. - Inventory rose by 0.54% to CNY 82.26 million, making up 3.79% of total assets[59]. - Long-term equity investments increased by 1.59% to CNY 101.60 million, now 4.68% of total assets[59]. - The total liabilities slightly increased from RMB 570,982,246.81 to RMB 574,312,493.85, indicating a rise of about 0.58%[145]. Strategic Initiatives - The company plans not to distribute cash dividends or issue bonus shares[7]. - The company plans to launch a liver disease big data platform in Q4 2018, enhancing patient experience in chronic disease management[32]. - The company is actively expanding its sales channels by shifting from hospital sales to retail sales to mitigate the impact of bidding price limits[26]. - The company is focusing on local production in China and establishing long-term partnerships with pharmaceutical companies and hospitals[29]. - The company plans to focus on expanding its market presence and investing in new technologies to drive future growth[158]. Research and Development - Research and development investment reached 40,200,930.01 yuan, accounting for 10.36% of total revenue[50]. - The company plans to continue enhancing its R&D capabilities, focusing on liver disease diagnostic technologies and related applications[53]. - The company is focusing on the development of liver fibrosis diagnostic products, integrating various liver disease testing methods, and applying medical information technology tools[83]. - The R&D efforts will be concentrated in France, leveraging the expertise of the subsidiary Echosens in liver disease diagnostics to maintain a leading edge in the field[83]. Market Position and Competition - The company achieved a year-on-year sales revenue growth of 15.67% for its main product, the Compound Turtle Shell Soft Liver Tablets, during the reporting period[26]. - The market share of the Compound Turtle Shell Soft Liver Tablets in the anti-liver fibrosis traditional Chinese medicine sector exceeds 25%[26]. - The company anticipates increased competition in the liver disease diagnosis and treatment market due to rising health awareness and improved medical insurance systems[81]. - The company faces risks from a single main business focus, primarily in liver fibrosis treatment drugs and diagnostic equipment[80]. Corporate Governance and Compliance - The financial statements were prepared in accordance with the accounting standards issued by the Ministry of Finance, ensuring a true and complete reflection of the company's financial status and operating results[190]. - The financial statements were approved by the board of directors on August 29, 2018[186]. - The company confirmed that there were no penalties or rectification situations during the reporting period[96]. - The company is actively pursuing legal actions to protect its intellectual property rights[94]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 18,766[126]. - The largest shareholder, Wang Guanyi, holds 11.31% of the shares, totaling 29,754,138 shares[127]. - The total number of restricted shares at the end of the period was 35,086,378 shares, after accounting for the unlocked shares[124]. - The company completed the unlocking of 96,000 restricted stocks, accounting for 0.0365% of the total share capital, as part of its stock incentive plan[98].

Financial Performance - Total revenue for Q1 2018 reached ¥174,973,279.78, an increase of 13.28% compared to ¥154,464,955.00 in the same period last year[9] - Net profit attributable to shareholders was ¥10,116,444.70, representing a growth of 19.24% from ¥8,483,748.91 year-on-year[9] - Basic earnings per share rose to ¥0.038, an increase of 8.57% compared to ¥0.035 in the same period last year[9] - The company's net profit attributable to shareholders increased by 19.24% year-on-year, contributing to overall performance growth[25] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 10,048,083.41, up by 14.68% year-on-year[26] - The company reported a decrease in expenses compared to the previous year, contributing to improved profitability[26] - The net profit for Q1 2018 reached CNY 16,864,501.86, compared to CNY 14,214,539.65 in Q1 2017, indicating a year-over-year increase of about 18.6%[50] - The gross profit margin improved, with operating profit for Q1 2018 at CNY 24,522,108.42, up from CNY 21,032,931.05 in Q1 2017, reflecting a growth of approximately 16.4%[50] Cash Flow - Net cash flow from operating activities improved significantly to ¥3,697,824.28, a 226.01% increase from a negative cash flow of ¥2,934,498.99 in the previous year[9] - The total cash inflow from operating activities was ¥163,262,491.82, while cash outflow was ¥159,564,667.54, resulting in a net cash flow of ¥3,697,824.28[58] - The company reported a net increase in cash and cash equivalents of ¥99,403,082.01 for the quarter, contrasting with a decrease of ¥46,419,101.70 in the previous year[63] - The ending balance of cash and cash equivalents was ¥174,681,890.94, compared to ¥118,170,253.45 at the end of Q1 2017[63] - Cash inflow from financing activities totaled ¥104,962,415.37, up from ¥51,600,000.00 in the same period last year, leading to a net cash outflow of ¥51,700,880.41[59] Assets and Liabilities - Total assets decreased by 6.65% to ¥2,336,268,047.33 from ¥2,502,614,057.97 at the end of the previous year[9] - Current liabilities increased to CNY 335,213,316.21 from CNY 217,952,154.52, marking a significant rise of 53.6%[43] - The company's total liabilities increased to CNY 687,187,990.28 from CNY 570,982,246.81, reflecting a growth of 20.5%[43] - The total equity attributable to shareholders decreased to CNY 1,399,945,149.92 from CNY 1,502,520,319.04, a decline of 6.8%[44] Strategic Initiatives - The company plans to expand its business scope through acquisitions in medical devices, therapeutic drugs, and medical services to enhance profitability and risk resistance[11] - The company aims to accelerate its strategic transformation and diversify its product offerings to mitigate risks associated with industry competition and policy changes[12] - The company is focusing on developing diagnostic products for liver fibrosis, integrating various liver disease detection methods, and utilizing medical information technology tools[14] - The company plans to continue expanding its market presence and product development, focusing on internal R&D advancements[25] Risks and Challenges - The company faces risks from rising raw material prices, particularly for Cordyceps, which may impact product gross margins[13] - The company is currently facing important risk factors that may adversely affect future operations, as detailed in the report[26] - The company has implemented measures to address major difficulties in operations as outlined in the report[26] Shareholder Information - The top ten shareholders include Wang Guanyi with 11.31% and China National Investment & Guaranty Corporation with 9.18% of shares[16] - The company has committed to avoiding any business competition with its wholly-owned and holding enterprises, ensuring no new investments in similar business operations[31] - The company has fulfilled its commitment to avoid transferring or entrusting the management of its shares for 36 months post-IPO[30] - The company has confirmed that it will not seek to become the controlling shareholder of Furu Medical Technology Co., Ltd. in any form[30] - The company has ensured that its shareholders will not engage in activities that may harm the interests of Furu Medical Technology Co., Ltd. and its other shareholders[31] Investment Activities - Short-term borrowings rose by 134% to CNY 175,490,030.96 due to temporary funding for acquiring shares in Echosens, a French company[24] - Investment cash payments surged by 1336% to CNY 157,955,043.56 for acquiring part of Echosens' equity during the reporting period[24] - The company is in the process of acquiring shares from the shareholders of Echosens, with a total of 12,434 shares being acquired, resulting in a 50.39% ownership stake in Echosens[28] - The total amount raised from the IPO was RMB 505.24 million, with RMB 378.95 million being excess funds[34] - The company used RMB 184.13 million of excess funds to acquire 100% of Echosens in France, completing the acquisition by June 29, 2011[34]

Financial Performance - The company's operating revenue for 2017 was ¥849,675,042.33, representing a 2.74% increase compared to ¥826,987,166.98 in 2016[17] - The net profit attributable to shareholders for 2017 was ¥71,866,910.82, a decrease of 40.63% from ¥121,047,929.99 in 2016[17] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥73,346,797.89, down 38.82% from ¥119,889,414.85 in the previous year[17] - The net cash flow from operating activities was ¥126,160,834.06, a decline of 15.24% compared to ¥148,843,876.72 in 2016[17] - Basic earnings per share for 2017 were ¥0.27, a decrease of 41.30% from ¥0.46 in 2016[17] - The total assets at the end of 2017 amounted to ¥2,502,614,057.97, reflecting a 3.99% increase from ¥2,406,635,582.65 at the end of 2016[17] - The net assets attributable to shareholders at the end of 2017 were ¥1,502,520,319.04, up 2.75% from ¥1,462,369,062.35 in 2016[17] - The weighted average return on equity for 2017 was 5.16%, down from 8.65% in 2016[17] - The company reported a total non-recurring loss of CNY 1,479,887.07 in 2017, compared to a gain of CNY 1,158,515.14 in 2016[23] - The company achieved total revenue of 849.675 million yuan in 2017, representing a year-on-year growth of 2.74%[43] - The company reported a significant increase in financial expenses due to exchange losses from USD to EUR, with a change of -1,620.70%[68] - The total revenue for the year 2017 was approximately 34.7 million, showing a significant increase compared to previous years[163] - The company reported a net profit of 701,300, indicating a strong financial performance[163] Dividend Policy - The company plans to distribute a cash dividend of ¥1.00 per 10 shares to all shareholders based on the total share capital as of December 31, 2017[6] - The company announced a cash dividend of CNY 1.00 per 10 shares, totaling CNY 26,305,310.00 for the reporting period, which represents 100% of the distributable profit[106] - The total distributable profit for the year was CNY 382,858,308.40, indicating a strong profitability position[106] - The cash dividend payout ratio for 2017 was 36.60% of the net profit attributable to ordinary shareholders, compared to 21.75% in 2016 and 28.71% in 2015[109] - The company has consistently maintained a cash dividend distribution of CNY 1.00 per 10 shares for the past three years[107] - The cash dividend represents the entirety of the profit distribution for the year, reflecting a commitment to returning value to shareholders[106] Research and Development - The company invested CNY 86,113,094.43 in R&D for diagnostic equipment, representing 10.13% of its operating revenue[28] - Research and development investment increased to 86,113,094.43, representing 10.13% of operating revenue, up from 7.99% in 2016[69] - The number of research and development personnel rose to 133, accounting for 20.45% of the workforce, compared to 19.05% in 2016[70] - The company is focusing on new technology research and development to improve its product offerings[170] Market Expansion and Strategy - The company plans to expand its sales channels and strengthen cooperation with hospitals and retail channels to stabilize and grow sales revenue[26] - The company has actively pursued partnerships and joint ventures to introduce advanced diagnostic technologies into the Chinese market[34] - The company is actively expanding its medical device market in North America, Asia-Pacific, and China, adjusting strategies based on local conditions[49] - The company plans to enhance cooperation with hospitals and expand retail channels to adapt to pharmaceutical cost control policies[50] - The company is expanding its market presence, targeting a 30% increase in market share in the next two years[178] - The company plans to enter international markets, with an initial investment of 100 million RMB allocated for expansion efforts[178] Product Performance - The sales revenue of Echosens in 2017 was €65,065,625, reflecting a year-on-year growth of 25.41%[28] - Sales revenue from diagnostic instruments increased by 26.18% year-on-year, while pharmaceutical sales revenue declined due to bidding price limits and sales model adjustments[43] - The company achieved sales of 853 FibroScan devices in 2017, representing a year-on-year growth of 26.18%[49] - Revenue from medical devices accounted for 58.09% of total revenue, with a year-on-year increase of 33.75%[56] - The company's proprietary drug sales decreased by 33.87%, contributing €232,000,340.09 to total revenue[58] - The market share of the proprietary drug, Fufang Bie Jia Ru Gan Pian, exceeds 25%, making it the leading product in the anti-liver fibrosis category[50] Operational Efficiency - The company has upgraded its mobile medical service platform to enhance patient-doctor interactions and streamline appointment and consultation processes[46] - The company is focused on enhancing operational efficiency and expanding its service capabilities[167] - Operational efficiency improvements are expected to reduce costs by 5%, translating to savings of approximately 75 million RMB annually[178] Governance and Compliance - The company has established a comprehensive governance structure, including various rules and regulations to ensure compliance and promote healthy development[190] - There are no significant discrepancies between the company's governance practices and the regulatory requirements set by the China Securities Regulatory Commission[191] - The company operates independently from its major shareholders in terms of business, assets, personnel, institutions, and finances, maintaining a self-sufficient operational capability[192] Shareholder Structure - The company has a diversified shareholder structure, with no other shareholders holding more than 10% of the shares[157] - The largest shareholder, Wang Guanyi, holds 11.31% of the shares, totaling 29,754,138 shares, with a recent increase of 22,315,603 shares[152] - The company’s stock structure remains stable, with no significant impact on asset and liability structure from the repurchase[150] Employee Management - The total remuneration for the board of directors, supervisors, and senior management in 2017 was 4.6994 million CNY[179] - The company has a total of 649 employees, with 222 in sales, 133 in technical roles, and 90 in production[182] - The remuneration for the chairman was 567,500 CNY, while the total remuneration for the general manager was 758,700 CNY[180] - The company has established a performance-based bonus system, with performance bonuses typically ranging from 15% to 20% of monthly salaries[184] Future Outlook - Future guidance indicates a positive outlook for revenue growth and profitability in the upcoming fiscal periods[163] - The company aims to explore potential mergers and acquisitions to strengthen its market position[167]

Financial Performance - Total revenue for Q1 2018 reached ¥174,973,279.78, an increase of 13.28% compared to ¥154,464,955.00 in the same period last year[9] - Net profit attributable to shareholders was ¥10,116,444.70, representing a growth of 19.24% from ¥8,483,748.91 year-on-year[9] - Basic earnings per share rose to ¥0.038, an increase of 8.57% compared to ¥0.035 in the same period last year[9] - The company's net profit attributable to shareholders increased by 19.24% year-on-year, contributing to overall performance growth[25] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 10,048,083.41, up by 14.68% year-on-year[26] - The total operating revenue for the first quarter of 2018 was CNY 174,973,279.78, an increase of 13.4% compared to CNY 154,464,955.00 in the same period last year[49] - The net profit for Q1 2018 reached CNY 16,864,501.86, compared to CNY 14,214,539.65 in Q1 2017, indicating a year-over-year increase of about 18.6%[50] - The gross profit margin improved, with operating profit at CNY 24,522,108.42, up from CNY 21,032,931.05, reflecting a growth of approximately 16.5%[50] - The total comprehensive income for Q1 2018 was CNY 8,575,514.84, down from CNY 16,191,903.28 in Q1 2017, showing a decrease of approximately 47.1%[51] Cash Flow - Net cash flow from operating activities improved significantly to ¥3,697,824.28, a 226.01% increase from a negative cash flow of ¥2,934,498.99 in the previous year[9] - The company reported a total cash inflow from operating activities of ¥163,262,491.82, compared to ¥189,962,827.88 in the previous year, showing a decrease in operational cash generation[58] - Total cash outflow from operating activities was ¥159,564,667.54, down from ¥192,897,326.87 in Q1 2017, indicating improved cost management[58] - Cash inflow from financing activities totaled ¥104,962,415.37, up from ¥51,600,000.00 in Q1 2017, reflecting increased borrowing and investment[59] - The net cash flow from financing activities was -¥51,700,880.41, compared to -¥1,278,702.85 in the same quarter last year, indicating higher outflows for debt repayment and dividends[59] Assets and Liabilities - Total assets decreased by 6.65% to ¥2,336,268,047.33 from ¥2,502,614,057.97 at the end of the previous year[9] - The total liabilities increased to ¥687,187,990.28 from ¥570,982,246.81, marking an increase of 20.4%[43] - The total owner's equity decreased to ¥1,649,080,057.05 from ¥1,931,631,811.16, a decline of 14.6%[44] - Long-term equity investments decreased slightly to CNY 477,522,790.04 from CNY 479,654,239.12, a decline of 0.5%[45] - The company reported a total of RMB 1.06 billion in current assets, a decrease from RMB 1.23 billion[41] Shareholder Information - The company reported a total of 263,053,100 common shareholders at the end of the reporting period[15] - The top shareholder, Wang Guanyi, holds 11.31% of the shares, with a total of 29,754,138 shares[16] Strategic Plans and Market Position - The company plans to expand its business scope through acquisitions in medical devices, therapeutic drugs, and medical services to mitigate risks associated with its single business focus[11] - The company is facing increased competition in the liver disease diagnosis and treatment market, prompting a strategic shift to diversify its product offerings beyond liver disease[12] - The company is focusing on developing a series of diagnostic products based on physical, blood, biochemical, and genetic testing for liver fibrosis[14] - The company has ongoing plans for market expansion and potential acquisitions, including the acquisition of shares in Echosens[27] - The company holds 50.39% of the total equity of Echosens after the acquisition of 12,434 shares[28] Investment and Expenses - Short-term borrowings surged by 134% to CNY 175,490,030.96, due to temporary funding for acquiring shares in Echosens, a French company[24] - Investment cash payments skyrocketed by 1336% to CNY 157,955,043.56, related to the acquisition of Echosens shares[24] - Cash dividends paid increased by 8216% to CNY 156,239,317.85, as Echosens distributed cash dividends during the reporting period[24] - The company reported a significant increase in sales expenses, totaling CNY 53,435,395.49, compared to CNY 52,015,417.61 in the previous year, which is an increase of about 2.7%[50] - The company experienced an asset impairment loss of CNY 2,535,146.33, compared to a gain of CNY 426,014.76 in the previous year, indicating a significant shift in asset valuation[50] Research and Development - The company plans to continue internal research and development, with cash outflows for fixed assets and intangible assets rising by 229% to CNY 10,357,170.49[24] Other Financial Metrics - The company reported a decrease in expenses compared to the previous year, contributing to improved profitability[26] - The company is currently facing significant risk factors that may adversely affect future operations, as detailed in the report[26] - The company has no non-operating fund occupation by controlling shareholders during the reporting period[37]

Financial Performance - Operating revenue for the current period decreased by 2.28% to CNY 171,311,779.22, while year-to-date revenue increased by 10.41% to CNY 583,180,009.35[8] - Net profit attributable to shareholders decreased by 3.61% to CNY 9,443,655.97 for the current period, and year-to-date net profit decreased by 8.07% to CNY 49,064,757.32[8] - Basic and diluted earnings per share remained unchanged at CNY 0.04 for the current period[8] - The total operating revenue for the third quarter was CNY 171,311,779.22, a decrease of 0.57% compared to CNY 175,308,223.56 in the previous period[36] - The net profit for the third quarter was CNY 15,314,773.09, down from CNY 18,858,992.59 year-over-year[38] - The total profit for the third quarter was CNY 24,971,812.55, compared to CNY 34,854,672.01 in the same period last year, reflecting a decline of approximately 28.4%[38] - The company's total profit for Q3 2017 was CNY 90.30 million, a slight decrease of 3.56% from CNY 93.63 million in Q3 2016[46] Cash Flow - Net cash flow from operating activities decreased by 43.21% to CNY 56,888,765.83 year-to-date[8] - The company's net cash flow from financing activities was CNY -16,275,201.47, compared to CNY -3,172,412.74 in the previous year[55] - The ending balance of cash and cash equivalents was CNY 251,815,324.36, up from CNY 179,520,933.56 in the same period last year, representing a 40% increase[55] - Cash inflow from financing activities totaled CNY 136,560,000.00, a decrease from CNY 145,390,000.00 year-on-year[55] - The company recorded a net increase in cash from operating activities of CNY 631.05 million, compared to CNY 597.14 million in the previous year[52] - Total cash inflow from operating activities reached CNY 756,817,040.65, up from CNY 438,850,771.58 year-on-year, reflecting a growth of 72%[54] Assets and Liabilities - Total assets increased by 3.20% to CNY 2,483,693,292.08 compared to the end of the previous year[8] - Non-current assets totaled CNY 1,230,453,081.03, an increase from CNY 1,116,238,935.75, reflecting a growth of about 10.2%[31] - The total liabilities decreased slightly to CNY 575,372,100.11 from CNY 581,151,219.22, a reduction of about 1.3%[30] - The equity attributable to shareholders of the parent company increased to CNY 1,477,018,761.30 from CNY 1,462,369,062.35, reflecting a growth of approximately 1%[31] - Long-term equity investments surged by 493% due to new investments in Hangzhou Ruiying Health Industry Equity Investment Fund[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 19,882[12] - The largest shareholder, Wang Guanyi, holds 11.31% of the shares, amounting to 29,754,138 shares[12] - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[13] Expenses - The company’s management expenses rose by 46% due to IPO costs incurred by its French subsidiary[19] - Financial expenses skyrocketed by 3321% primarily due to foreign exchange losses from USD-denominated assets[19] - The company's management expenses increased to CNY 47,698,037.93 from CNY 40,166,749.24, representing a rise of about 18.8%[38] - The sales expenses for the third quarter were CNY 48,342,165.81, slightly down from CNY 50,466,078.62 in the previous year[38] Other Financial Metrics - Weighted average return on equity decreased by 0.08% to 0.64% for the current period[8] - The company reported non-operating income and expenses totaling CNY -1,046,707.57 year-to-date[9] - The company reported a significant decrease of 81% in notes receivable due to the maturity of certain notes during the period[19] - Other receivables increased by 95% as a result of increased business loans and payment of business guarantees[19] - The company’s inventory decreased slightly by 2.9% from RMB 61 million to RMB 59 million[28] - The company has no overdue commitments from shareholders or related parties during the reporting period[22]

Financial Performance - Total revenue for the first half of 2017 was CNY 411,868,230.13, representing a 16.72% increase compared to CNY 352,874,345.95 in the same period last year[18]. - Net profit attributable to shareholders decreased by 9.08% to CNY 39,621,101.35 from CNY 43,576,341.39 year-on-year[18]. - Basic earnings per share decreased by 5.88% to CNY 0.16, compared to CNY 0.17 in the same period last year[18]. - The company reported a decrease in net profit after deducting non-recurring gains and losses by 4.43% to CNY 40,999,689.14 from CNY 42,898,637.65 year-on-year[18]. - The company reported an operating profit of ¥68,288,149.65, reflecting a year-on-year increase of 17.98%[46]. - The total profit amounted to ¥65,327,530.17, which is an 11.14% increase from the previous year[46]. - Net profit for the period was ¥51,767,413.69, showing a growth of 3.05% year-on-year[46]. - The company reported a total comprehensive income of CNY 103,289,776.41, compared to CNY 98,923,632.07 in the previous period, showing an increase of about 4.4%[153]. - The company achieved a net cash inflow from investment activities of CNY 50,866,807.21, a significant improvement compared to a net outflow of CNY 25,355,287.27 in the previous period[159]. Cash Flow and Investments - Net cash flow from operating activities dropped significantly by 57.22% to CNY 29,772,348.21, down from CNY 69,586,617.86 in the previous year[18]. - The net cash flow from investment activities increased significantly by 300.62% to ¥50,866,807.21, due to the maturity of financial products[51]. - The total cash outflow for investment activities was ¥150,756,204.24, significantly higher than ¥6,834,450.90 in the previous period, reflecting aggressive investment strategies[163]. - The company received ¥50,000,000.00 from investment recoveries, indicating a strategic focus on liquidating investments[163]. Assets and Liabilities - Total assets increased by 1.01% to CNY 2,430,983,076.35 from CNY 2,406,635,582.65 at the end of the previous year[18]. - Total liabilities include long-term borrowings of ¥150,000, unchanged at 0.01% of total assets[60]. - The total non-current assets amounted to CNY 1,143,589,615.48, up from CNY 1,116,238,935.75, marking an increase of about 2.44%[143]. - The company’s short-term borrowings decreased to CNY 50,000,000.00 from CNY 70,000,000.00, a reduction of approximately 28.57%[143]. Market and Product Development - The company has established "Liver Health Management Centers" since 2013, integrating resources for chronic liver disease treatment, including diagnostics, pharmaceuticals, and health management services[26]. - The company aims to establish a complete ecosystem for liver disease management, integrating upstream pharmaceutical production and downstream patient management[26]. - The company is actively transforming into a medical service enterprise, leveraging over 20 years of experience in the liver disease field to deepen hospital collaborations[28]. - The company is focusing on developing diagnostic products in the liver fibrosis field, integrating various liver disease testing methods, and applying medical information technology tools[84]. - The company has successfully expanded its overseas market, with rapid growth in diagnostic instrument sales aligning with expectations[34]. Strategic Initiatives - The company plans to accelerate its strategic transformation and actively promote business structure adjustments to enhance market competitiveness and adapt to industry policies[82]. - The company is participating in national healthcare reforms, including the promotion of zero-price drug policies and tiered diagnosis and treatment systems[37]. - The company aims to establish a global consensus on liver fibrosis diagnosis and treatment, focusing on comprehensive solutions for liver diseases[41]. - The company has committed to investing RMB 50 million in research and development for innovative healthcare solutions over the next year[90]. Shareholder and Equity Information - The company completed the first grant of restricted stock incentive plan, granting a total of 4,772,000 shares to 81 incentive objects[97]. - The total number of shareholders at the end of the reporting period was 20,922[124]. - The largest shareholder, Wang Guanyi, holds 11.31% of the shares, totaling 29,754,138 shares[124]. - The total number of restricted shares at the end of the period was 35,194,378 shares, with 2,474,272 shares released during the period[122]. - The company approved the repurchase and cancellation of 193,022 restricted stocks at a price of 3.915 RMB per share, reducing total shares from 263,246,122 to 263,053,100[184]. Corporate Governance and Compliance - The financial statements are prepared based on actual transactions in accordance with the accounting standards issued by the Ministry of Finance, ensuring a true and complete reflection of the company's financial status[188]. - The company has evaluated its ability to continue as a going concern and found no significant doubts regarding its operational viability[187]. - The company did not engage in any major related party transactions during the reporting period[100]. - The company has not initiated any poverty alleviation work or environmental protection measures during the reporting period[111].